Press review


Gates foundation partners with German biotech Evotec in tuberculosis research

BERLIN, 14 June (APM) - The Bill and Melinda Gates Foundation will pay German biotech Evotec up to $23.8 million in a five-year partnership for tuberculosis drug research and development, Frankfurter Allgemeinee Zeitung (FAZ) reported on Tuesday (p22).
Evotec is to generate a database for the selection of the best drug combinations against lung disease linked to tuberculosis, Evotec told FAZ.
It is a new trend that foundations support early drug development by universities and biotechs, Evotec's chief executive Werner Lanthaler said.

Paul Hudson appointed to boost Sanofi's growth

Novartis' Paul Hudson has been appointed Sanofi's new chief executive to boost growth, FAZ said on Saturday (p22) and Handelsblatt on Tuesday (p46) (APMHE 63257).
Sanofi has lost touch in the oncology business and its cholesterol drug Praluent (alirocumab) is a flop. Among the recent launches, only Dupixent (dupilumab) seems to meet the expectations, Handelsblatt said.
Many experts think that Hudson's influence was key to Novartis' success in launching new drugs over the past three years
Many experts think that Hudson's influence was key to Novartis' success in launching new drugs over the past three years. Moreover, he promoted digitisation at Novartis on chief executive Vas Narasimhan's initiative and this is key for any pharma company currently, FAZ said.

Novartis' Tschudin will deal with pricing talks on Zolgensma

Marie-France Tschudin, who was appointed to succeed Paul Hudson, will have to deal with the pricing talks on gene therapy Zolgensma (onasemnogene abeparvovec) that are expected to be tough, Handelsblatt said on Tuesday (p46).
Tschudin joined Novartis in 2017 as head of pharma for Europe. Previously, she had worked for 10 years for Celgene.
Tschudin is the third woman to join Novartis' board of directors after general counsel Shan­non Thy­me Klin­ger and head of oncology Su­san­ne Schaf­fert, FAZ reported on Sunday (p22).

German pharma managers are the top earners

German pharma managers are the top earners among industrial sectors, according to a survey by job recruitment firm Stepstone, Die Welt said on Sunday (p42).
Around 17% of workers in this sector earn more than €100,000 a year, which is the highest proportion in the survey.

Stada buys GSK's consumer health brands

German generics manufacturer Stada will acquire a portfolio of five skin care brands and a paediatric cough medicine from GlaxoSmithKline, FAZ reported on Saturday (p21) (APMHE 63266).
The deal is worth €100 million, while sales of the six brands are £30 million a year, according to FAZ. Stada will relocate the production to its UK subsidiary Thornton & Ross.

J&J tipped

Johnson & Johnson is among the 10 companies recommended to investors by Handelsblatt on Friday (p47).
J&J has invested a lot in new drugs and products in its three business areas (pharmaceutical, medical devices and health consumer goods) and has made strategic takeovers, such as that of Swiss biotechnology company Actelion.
A quarter of its turnover comes from the products that were launched in the past five years, Handelsblatt says.

Novo Nordisk to put an end to insulin injection for type 2 diabetes patients

Novo Nordisk, also recommended to shareholders by Handelsblatt on Friday (p49), is about to put an end to insulin injection for type 2 diabetes patients.
The Danish company has succeeded to keep its leading position in insulin products while outrunning its main U.S. competitor Lilly, the paper said. Novo's oral version of Ozempic (semaglutide) has shown very positive results and may be launched in Europe and the U.S. in 2019.



Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.